Skip to main navigation Skip to search Skip to main content

Risk of antidepressant-induced tardive dyskinesia: a scoping review of evidence and high-risk agents

  • Carlos Siopa*
  • , Leonor Correia
  • , Maria João Estribeiro
  • , Inês Chaves
  • , Pedro Câmara Pestana
  • *Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

Abstract

Purpose of Review: Antidepressants are widely prescribed, but potentially persistent adverse effects, such as tardive dyskinesia, are increasingly recognized. The literature on antidepressant-induced tardive dyskinesia (AITD) remains largely based on case reports and small observational studies, with potential confounding by concomitant medications. This scoping review maps the available evidence on antidepressant-induced tardive dyskinesia, including its occurrence and clinical characteristics, and was conducted in accordance with the Joanna Briggs Institute methodology and reported following the PRISMA-ScR guidelines. A comprehensive search was conducted in PubMed (MEDLINE), PsycINFO, Cochrane Library, and Google Scholar. Two reviewers independently screened and reviewed included studies, achieving complete agreement throughout the selection process. Recent Findings: Thirty-nine reports were reviewed, including 31 case reports, 5 case series, 1 prospective prevalence study, 1 retrospective cross-sectional study, and 1 pharmacovigilance study. The most frequently reported drugs were selective serotonin reuptake inhibitors, with fluoxetine accounting for the largest number of published reports. Clinical latency ranged from less than 24 h to approximately 10 years of exposure, and the most frequent symptoms were orofacial and buccolingual dyskinesias. Observational evidence identified prevalence estimates of tardive dyskinesia ranging from 3.2% to 6%, while pharmacovigilance data demonstrated significant disproportionality signals for amoxapine and venlafaxine. Summary: Antidepressants may be associated with tardive dyskinesia, particularly serotonergic antidepressants. The current evidence remains insufficient to establish definitive causality or a clear comparative risk across antidepressant classes. Prospective cohort studies and pharmacovigilance registries are needed to better characterize the incidence, risk factors, mechanisms, and long-term outcomes of AITD.
Original languageEnglish
Article number22
Number of pages28
JournalCurrent Treatment Options in Psychiatry
Volume13
Issue number1
DOIs
Publication statusPublished - Dec 2026

Keywords

  • Antidepressants
  • Drug-induced movement disorders
  • Extrapyramidal symptoms
  • Pharmacovigilance
  • Selective serotonin reuptake inhibitors
  • Tardive dyskinesia

Fingerprint

Dive into the research topics of 'Risk of antidepressant-induced tardive dyskinesia: a scoping review of evidence and high-risk agents'. Together they form a unique fingerprint.

Cite this